Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec and Sobi report positive data for haemophilia drug

Biogen Idec and Sobi report positive data for haemophilia drug

3rd July 2013

Biogen Idec and partner Sobi have presented positive new findings from a study of their long-lasting recombinant factor IX candidate Alprolix.

Data from the phase III B-LONG study has demonstrated the drug's efficacy in reducing the number of acute bleeding episodes among haemophilia B patients, both under normal circumstances and in perioperative settings.

Meanwhile, analysis of a population pharmacokinetics model developed for Alprolix demonstrated that it was able to accurately predict peak and trough factor IX activity levels achieved in the B-LONG study across a variety of dose specifications.

Dr Glenn Pierce, senior vice-president of global medical affairs and chief medical officer of Biogen Idec’s haemophilia division, said: "The data presented today supports the potential of the therapy to reduce the frequency of prophylactic infusions for patients with haemophilia B."

Further information from B-LONG presented earlier this year also revealed that the drug can help to control bleeding with fewer injections than the current standard of care.ADNFCR-8000103-ID-801607411-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.